Temozolomide may improve the outlook for patients with recurrent malignant gliomas

被引：0
作者：
不详
机构：
来源：
Drugs & Therapy Perspectives | 2000年 / 15卷 / 1期
关键词：
Thalidomide; Temozolomide; Malignant Glioma; Glioblastoma Multiforme; Anaplastic Astrocytoma;
D O I：
10.2165/00042310-200015010-00001
中图分类号：
学科分类号：
摘要：
Temozolomide is an orally active imidazotetrazine analogue of dacarbazine. As this drug is relatively new, data evaluating its efficacy are limited. Based on the available information, temozolomide is effective in patients with recurrent malignant gliomas. Specifically, temozolomide has shown efficacy in patients with recurrent anaplastic astrocytoma or mixed grade 3 oligoastrocytoma and appears to improve survival to a greater extent than procarbazine in patients with recurrent glioblastoma multiforme. Quality-of-life assessments are now being included in clinical trials because of the small and short-lived benefit in overall survival associated with treatment regimens for this disease. Temozolomide appears to improve quality of life in patients with recurrent gliomas. Temozolomide has also shown efficacy in newly diagnosed malignant glioma, primarily glioblastoma multiforme, when used prior to radiotherapy. This drug has shown benefit in various types of malignant gliomas, however, whether its potential is confirmed in future clinical trials will be awaited with interest.
引用
收藏
页码：1 / 5
页数：4
相关论文
共 18 条
  • [1] Temodar Prescribing Information, (1999)
  • [2] Hvizdos K., Goa K., Temozolomide, CNS Drugs, 12, 3, pp. 237-243, (1999)
  • [3] Partial backing for temozolomide from US ODAC, Pharma Marketletter, 18, (1999)
  • [4] Newlands E., Temozolomide, CNS Drugs, 12, 3, (1999)
  • [5] Friedman H., Temozolomide, CNS Drugs, 12, 3, (1999)
  • [6] Biochemical actions and clinical use of temozolomide, Pharm J, 262, (1999)
  • [7] Prados M., Yung A., Chang S., Et al., A phase II trial of Temodal® (temozolomide) in patients with anaplastic astrocytoma at first relapse, 35th Proc Am Soc Clin Oncol, 18, (1999)
  • [8] Schering Temodal® tumor response supports astrocytoma, not glioblastoma, FDC Pink, 61, pp. 3-4, (1999)
  • [9] Yung A., Levin V.A., Albright R., Et al., Randomized trial of Temodal vs. procarbazine in glioblastoma multiforme at first relapse, 35th Proc Am Soc Clin Oncol, 18, (1999)
  • [10] British National Formulary No. 38, (1999)
12